Thus, acute coronary syndrome (ACS) patients with DM/obesity who have undergone PCI and are intermediate CYP2C19 metabolizers may yield better treatment outcomes if prescribed ticagrelor instead of clopidogrel. This evidence concerns the gene CYP2C19 and diabetes mellitus.